Literature DB >> 10203431

Quality of life in arthritis patients using nonsteroidal anti-inflammatory drugs.

I Wiklund1.   

Abstract

Arthritis is a painful and disabling condition. To suppress the pain and the inflammatory process, patients are often chronic nonsteroidal anti-inflammatory drug (NSAID) users. Chronic use of NSAIDs may induce peptic ulcer, dyspeptic problems and heartburn. Therefore, these patients are often provided with treatment to relieve and/or protect against gastrointestinal problems. Rheumatic disorders also affect a range of health-related quality of life domains. In one study, patients with NSAID-associated gastroduodenal lesions complained about lack of energy, sleep disturbances, emotional distress and social isolation in addition to pain and mobility limitations. The degree of distress and dysfunction differed markedly from scores in an unselected population. Clinical trial data suggest that acid-suppressing therapy with omeprazole is superior to therapy with misoprostol and ranitidine in healing gastroduodenal lesions and preventing abdominal pain, heartburn and indigestion symptoms during continued NSAID treatment. Because arthritic patients are severely incapacitated by their condition regarding most aspects of health-related quality of life, it is important to offer a treatment that is effective in healing and preventing NSAID-induced ulcers and gastrointestinal symptoms during continued NSAID treatment without further compromising the patients' quality of life. Treatment with omeprazole once daily has been shown to be superior to that with ranitidine and misoprostol in this respect.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10203431     DOI: 10.1155/1999/171408

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  5 in total

1.  A naturalistic study of the determinants of health related quality of life improvement in osteoarthritic patients treated with non-specific non-steroidal anti-inflammatory drugs.

Authors:  V Rabenda; N Burlet; O Ethgen; F Raeman; J Belaiche; J-Y Reginster
Journal:  Ann Rheum Dis       Date:  2004-11-04       Impact factor: 19.103

2.  Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.

Authors:  J K Marshall; J M Pellissier; C L Attard; S X Kong; M A Marentette
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  Esomeprazole for the management of upper gastrointestinal symptoms in patients who require NSAIDs: a review of the NASA and SPACE double-blind, placebo-controlled studies.

Authors:  Christopher J Hawkey; Lars-Erik Svedberg; Jørgen Naesdal; Claire Byrne
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 4.  Management of NSAID-induced gastrointestinal toxicity: focus on proton pump inhibitors.

Authors:  Marco Lazzaroni; Gabriele Bianchi Porro
Journal:  Drugs       Date:  2009       Impact factor: 9.546

5.  Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies.

Authors:  Christopher J Hawkey; Nicholas J Talley; James M Scheiman; Roger H Jones; Göran Långström; Jorgen Naesdal; Neville D Yeomans
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.